Previous attempts at risk stratification, using protein expression markers such as p16, Ki67 and COX [16], or an RT-PCR assay that estimates the risk of local recurrence [31], are limited by problems of intratumoral variability and reliance upon IBC rather than DCIS for gene selection. This evidence concerns the gene MKI67 and ductal breast carcinoma in situ.